DSpace Repository

Reduced insulin sensitivity as a marker for acute mountain sickness?

Show simple item record

dc.contributor.author Spliethoff, Kerstin
dc.contributor.author Meier, Daniela
dc.contributor.author Aeberli, Isabelle
dc.contributor.author Gassmann, Max
dc.contributor.author Langhans, Wolfgang
dc.contributor.author Maggiorini, Marco
dc.contributor.author Lutz, Thomas .A.
dc.contributor.author Goetze, Oliver
dc.date.accessioned 2022-01-04T20:29:59Z
dc.date.available 2022-01-04T20:29:59Z
dc.date.issued 2013
dc.identifier.uri https://hdl.handle.net/20.500.12866/10496
dc.description.abstract The diabetogenic side effects of dexamethasone should therefore be considered for AMS treatment. To examine whether reduced insulin sensitivity is predictive of AMS and how it is affected by dexamethasone at high altitude, we analyzed endocrine and metabolic parameters obtained from healthy mountaineers in Zurich (LA; 490 m), and 2 and 4 days after fast ascent to the Capanna Regina Margherita (HA2, HA4; 4559 m). 14 of 25 participants developed AMS and were treated with dexamethasone starting in the evening of HA2. Before and after ingestion of an 1800 kJ meal, plasma was analyzed for erythropoietin (EPO) and cholecystokinin (CCK). Insulin sensitivity (HOMA-S) and beta cell activity were calculated. HOMA-S (p<0.01) and EPO levels (p<0.05) were lower in Zurich in the group developing AMS and given dexamethasone, i.e., before treatment and exposure to hypoxia. CCK was lower (p<0.01) and glucose and insulin were higher on HA4 in the dexamethasone group compared to the untreated group. Individuals with low baseline insulin sensitivity and low baseline EPO levels were more susceptible to AMS. Reduced CCK may contribute to the beneficial effect of dexamethasone on high altitude anorexia. However, reduced insulin sensitivity questions the widespread use of dexamethasone to prevent/treat AMS. en_US
dc.language.iso eng
dc.publisher Mary Ann Liebert
dc.relation.ispartofseries High Altitude Medicine and Biology
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Humans en_US
dc.subject controlled study en_US
dc.subject altitude disease en_US
dc.subject Altitude Sickness en_US
dc.subject erythropoietin en_US
dc.subject Erythropoietin en_US
dc.subject Time Factors en_US
dc.subject altitude en_US
dc.subject Altitude en_US
dc.subject Insulin Resistance en_US
dc.subject Retrospective Studies en_US
dc.subject Anoxia en_US
dc.subject Oxygen en_US
dc.subject article en_US
dc.subject Blood Glucose en_US
dc.subject hypoxia en_US
dc.subject insulin en_US
dc.subject dexamethasone en_US
dc.subject Dexamethasone en_US
dc.subject acute disease en_US
dc.subject glucose en_US
dc.subject Interleukin-6 en_US
dc.subject acute mountain sickness en_US
dc.subject Acute mountain sickness en_US
dc.subject cholecystokinin en_US
dc.subject Cholecystokinin en_US
dc.subject Energy Intake en_US
dc.subject Glucocorticoids en_US
dc.subject Homeostasis en_US
dc.subject Hydrocortisone en_US
dc.subject Insulin resistance en_US
dc.subject insulin sensitivity en_US
dc.subject Insulin-Secreting Cells en_US
dc.subject Islet Amyloid Polypeptide en_US
dc.subject Models, Biological en_US
dc.subject mountaineering en_US
dc.subject pancreas islet beta cell en_US
dc.title Reduced insulin sensitivity as a marker for acute mountain sickness? en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1089/ham.2012.1128
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#1.06.00
dc.relation.issn 1557-8682

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


My Account